Peter Weisenseel

1.0k total citations
44 papers, 534 citations indexed

About

Peter Weisenseel is a scholar working on Immunology, Dermatology and Epidemiology. According to data from OpenAlex, Peter Weisenseel has authored 44 papers receiving a total of 534 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Immunology, 18 papers in Dermatology and 14 papers in Epidemiology. Recurrent topics in Peter Weisenseel's work include Psoriasis: Treatment and Pathogenesis (23 papers), Dermatology and Skin Diseases (15 papers) and Autoimmune Bullous Skin Diseases (7 papers). Peter Weisenseel is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (23 papers), Dermatology and Skin Diseases (15 papers) and Autoimmune Bullous Skin Diseases (7 papers). Peter Weisenseel collaborates with scholars based in Germany, United States and France. Peter Weisenseel's co-authors include Jörg C. Prinz, Kristian Reich, Thomas Ruzicka, Joerg C. Prinz, Kilian Eyerich, Andreas Pinter, Sven Wegner, Claudia Borelli, Knut Schäkel and Diamant Thaçi and has published in prestigious journals such as Journal of Investigative Dermatology, Journal of the American Academy of Dermatology and British Journal of Dermatology.

In The Last Decade

Peter Weisenseel

39 papers receiving 509 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter Weisenseel Germany	16	295	247	102	88	78	44	534
N. Doss Tunisia	14	335 1.1×	157 0.6×	108 1.1×	49 0.6×	55 0.7×	55	585
F. Cambazard France	15	295 1.0×	241 1.0×	132 1.3×	216 2.5×	32 0.4×	44	652
Aieska De Souza United States	12	501 1.7×	253 1.0×	214 2.1×	261 3.0×	35 0.4×	20	790
M. de la Brassinne Belgium	10	298 1.0×	305 1.2×	81 0.8×	102 1.2×	25 0.3×	26	506
R. de Lucas Spain	15	182 0.6×	98 0.4×	84 0.8×	124 1.4×	58 0.7×	60	614
Michael Buslau Germany	9	248 0.8×	353 1.4×	63 0.6×	115 1.3×	70 0.9×	19	596
Nicholas R. Telfer United Kingdom	7	159 0.5×	203 0.8×	60 0.6×	36 0.4×	32 0.4×	12	360
Omid Zargari Iran	12	113 0.4×	113 0.5×	69 0.7×	62 0.7×	54 0.7×	39	380
José Pedro Reis Portugal	14	427 1.4×	127 0.5×	224 2.2×	135 1.5×	38 0.5×	44	710
Marimar Sáez‐de‐Ocariz Mexico	11	198 0.7×	87 0.4×	68 0.7×	147 1.7×	32 0.4×	42	523

Countries citing papers authored by Peter Weisenseel

Since Specialization

Citations

This map shows the geographic impact of Peter Weisenseel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Weisenseel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Weisenseel more than expected).

Fields of papers citing papers by Peter Weisenseel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Weisenseel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Weisenseel. The network helps show where Peter Weisenseel may publish in the future.

Co-authorship network of co-authors of Peter Weisenseel

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Weisenseel. A scholar is included among the top collaborators of Peter Weisenseel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Weisenseel. Peter Weisenseel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gerdes, Sascha, et al.. (2025). Long‐Term Impact of Guselkumab on Skin, Sexuality, and Perceived Stigmatization in Patients With Psoriasis in Routine Clinical Practice: Week 76 Effectiveness and Safety Results From the Prospective German Multicenter G‐ EPOSS Study. The Journal of Dermatology. 52(9). 1368–1381.

Schäkel, Knut, Kilian Eyerich, Andreas Pinter, et al.. (2025). 62281 GUIDE Phase 3b trial results: early intervention with guselkumab results in higher rates of fingernail psoriasis clearance and maintenance of nail response following treatment withdrawal. Journal of the American Academy of Dermatology. 93(3). AB215–AB215.

Schäkel, Knut, Khusru Asadullah, Andreas Pinter, et al.. (2024). 50236 GUIDE trial results after withdrawal in part 3: Long-term remission in patients with psoriasis treated with guselkumab within 15 months from onset of symptoms. Journal of the American Academy of Dermatology. 91(3). AB222–AB222. 1 indexed citations

Birtle, Alison, Luigi Formisano, V. Descamps, Peter Weisenseel, & Antoni Vilaseca. (2024). Early Identification and Management of Patients with Rash on Apalutamide. Oncology and Therapy. 12(3). 609–620.

Chen, Ye, Julianty Angsana, Nadine Krüger, et al.. (2024). LB943 Prediction of super response and drug-free disease control in guselkumab patients using multivariate baseline serum biomarkers: data from part 3 of GUIDE trial. Journal of Investigative Dermatology. 144(8). S165–S165. 1 indexed citations

Schäkel, Knut, Kristian Reich, K. Asadullah, et al.. (2023). Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance (‘clinical super response’): Week 28 results from the ongoing phase IIIb randomized, double‐blind, parallel‐group, GUIDE study. Journal of the European Academy of Dermatology and Venereology. 37(10). 2016–2027. 46 indexed citations

Asadullah, K., et al.. (2022). 083 Prolonged Q16W treatment interval of guselkumab is non-inferior to Q8W dosing for maintaining disease control in super responders: primary results from GUIDE at Week 68 in patients with psoriasis. Journal of Investigative Dermatology. 142(12). S194–S194. 2 indexed citations

Thaçi, Diamant, Kilian Eyerich, Andreas Pinter, et al.. (2021). Direct comparison of risankizumab and fumaric acid esters in systemic therapy–naïve patients with moderate-to-severe plaque psoriasis: a randomized controlled trial. British Journal of Dermatology. 186(1). 30–39. 15 indexed citations

Eyerich, Kilian, Peter Weisenseel, Andreas Pinter, et al.. (2021). IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE). BMJ Open. 11(9). e049822–e049822. 54 indexed citations

10.

Burkhardt, Harald, Peter Weisenseel, Marc Alexander Radtke, & K. Krüger. (2016). Hautmalignome und immunmodulierende Antirheumatikatherapie. Zeitschrift für Rheumatologie. 75(1). 32–40. 2 indexed citations

11.

Weisenseel, Peter, Dagmar Wilsmann‐Theis, Christina R. Kahl, Kristian Reich, & Rotraut Mößner. (2016). Pustulöse Psoriasis. Der Hautarzt. 67(6). 445–453. 15 indexed citations

12.

Weisenseel, Peter & Kristian Reich. (2015). Psoriasis inversa. Der Hautarzt. 66(6). 408–412. 5 indexed citations

13.

Fleckenstein, Johannes, Sybille Krämer, Florian Pfab, et al.. (2009). Acupuncture in acute herpes zoster pain therapy (ACUZoster) – design and protocol of a randomised controlled trial. BMC Complementary and Alternative Medicine. 9(1). 31–31. 18 indexed citations

14.

Schauber, Jürgen, Peter Weisenseel, & Thomas Ruzicka. (2009). Topical treatment of perianal eczema with tacrolimus 0·1%. British Journal of Dermatology. 161(6). 1384–1386. 12 indexed citations

15.

Nast, Alexander, Matthias Augustin, Wolf‐Henning Boehncke, et al.. (2009). S3‐Leitlinie zur Therapie der Psoriasis vulgaris – Update: „Übersicht der Therapieoptionen” und „Efalizumab”. JDDG Journal der Deutschen Dermatologischen Gesellschaft. 8(1). 65–66. 5 indexed citations

16.

Weisenseel, Peter, et al.. (2008). Disseminated Eruptive Giant Mollusca Contagiosa in an Adult Psoriasis Patient during Efalizumab Therapy. Dermatology. 217(1). 85–86. 9 indexed citations

17.

Weisenseel, Peter, et al.. (2007). Relevance of the low-affinity type of the Fcγ-receptor IIIa-polymorphism in bullous pemphigoid. Archives of Dermatological Research. 299(3). 163–164. 14 indexed citations

18.

Borelli, Claudia, et al.. (2005). Deep Subcutaneous Application of Poly-<i>L</i>-Lactic Acid as a Filler for Facial Lipoatrophy in HIV-Infected Patients. Skin Pharmacology and Physiology. 18(6). 273–278. 31 indexed citations

19.

Weisenseel, Peter, et al.. (2005). Detection of the 47-kilodalton membrane immunogen gene of Treponema pallidum in various tissue sources of patients with syphilis. Diagnostic Microbiology and Infectious Disease. 51(2). 143–145. 27 indexed citations

20.

Spes, C, Volker Klauß, Harald Mudra, et al.. (1997). Quantitative Dobutamin-Streßechokardiographie in der Spätphase nach Herztransplantation: Normwerte und Befunde bei Patienten mit Transplantatvaskulopathie (Quantitative dobutamine stress echocardiography in patients late after heart transplantation: Normal values and findings in patients with cardiac allograft vasculopathy). Zeitschrift für Kardiologie. 86(10). 868–876. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact